Literature DB >> 7426353

Corticosteroids in chronic airways obstruction: can the patient's assessment be ignored?

I P Williams, C R McGavin.   

Abstract

In a study to examine the methods of assessing the response of patients with chronic airways obstruction to corticosteroids, 20 patients received a week of placebo tablets, followed by three weeks of prednisolone 30 mg daily. Subjective benefit was assessed by a visual analogue scale (VAS), and objective changes by spirometry and an exercise test. Significant increases in FEV1 and in exercise performance were observed after steroid therapy. Changes in FVC correlated both with VAS score and with changes in exercise performance. Changes in FEV1 correlated with neither. The good correlation between the changes in a ventilatory function test (the FVC) and the patients' assessments of the drug suggests that the non-specific euphoriant effect of steroids does not eclipse their specific action on ventilatory function. Assessment of benefit should include a subjective assessment and changes in FVC and exercise performance. Changes in FEV1 appear to have less clinical relevance.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7426353     DOI: 10.1016/0007-0971(80)90025-x

Source DB:  PubMed          Journal:  Br J Dis Chest        ISSN: 0007-0971


  4 in total

1.  Corticosteroids in stable chronic obstructive pulmonary disease: reappraisal of efficacy.

Authors:  J K Stoller; Z B Gerbarg; A R Feinstein
Journal:  J Gen Intern Med       Date:  1987 Jan-Feb       Impact factor: 5.128

2.  Corticosteroids in chronic bronchitis.

Authors:  R Rudd
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-26

Review 3.  Measurement of dyspnoea in chronic obstructive pulmonary disease.

Authors:  E G Eakin; R M Kaplan; A L Ries
Journal:  Qual Life Res       Date:  1993-06       Impact factor: 4.147

4.  Psychological changes and improvement in chronic airflow limitation after corticosteroid treatment.

Authors:  D M Mitchell; P Gildeh; M Rehahn; A Dimond; J V Collins
Journal:  Thorax       Date:  1984-12       Impact factor: 9.139

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.